Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Organicell Regenerative Medicine Inc
(OP:
OCEL
)
2.750
UNCHANGED
Last Price
Updated: 3:51 PM EST, Mar 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Organicell Regenerative Medicine Inc
RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
March 07, 2024
Via
ACCESSWIRE
Organicell Announces 1-for-200 Reverse Stock Split
November 27, 2023
Via
ACCESSWIRE
Organicell Reports Interim Results of Phase 1/2A Research Program
July 26, 2023
Via
ACCESSWIRE
Organicell Welcomes Howard Golub, MD, PhD As Its New EVP/CSO
June 29, 2023
Via
ACCESSWIRE
Organicell Welcomes Harry Leider, MD, MBA as its New CEO
June 21, 2023
Via
ACCESSWIRE
Organicell Starts Enrolling Long COVID Trial
November 17, 2022
Via
ACCESSWIRE
Organicell Activates COPD Trial at Mayo Clinic
November 15, 2022
Via
ACCESSWIRE
Organicell Regenerative Medicine, Inc. Announces Additions to Board of Directors
October 11, 2022
Via
ACCESSWIRE
Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses
December 27, 2022
To learn more about Organicell, download the latest research report here
Via
TheNewswire.com
Exposures
COVID-19
Product Safety
Organicell Regenerative Medicine, Inc. Responds to Recent Promotional Activities Pursuant to OTC Markets Request
November 21, 2022
Via
ACCESSWIRE
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Via
FinancialNewsMedia
Exposures
COVID-19
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
November 15, 2022
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END
Via
FinancialNewsMedia
Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team
September 20, 2022
Via
ACCESSWIRE
Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market
September 16, 2022
Via
ACCESSWIRE
BeautyHealth’s Hydrafacial Announces Partnership to Develop Breakthrough Exosome Booster
September 14, 2022
From
BeautyHealth
Via
Business Wire
Organicell Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial Enrollment
September 09, 2022
Via
ACCESSWIRE
Organicell Regenerative Medicine, Inc. Engages Law Firm McDermott Will & Emery
August 30, 2022
Via
ACCESSWIRE
Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round
August 26, 2022
Via
ACCESSWIRE
Organicell Announces Matt Sinnreich as CEO
July 26, 2022
Via
ACCESSWIRE
Organicell Announces Matt Sinnreich as CEO
July 26, 2022
MIAMI, FL / ACCESSWIRE / July 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological...
From
Organicell Regenerative Medicine, Inc.
Via
AccessWire
Topics
Derivatives
Exposures
Derivatives
Organicell Regenerative Medicine, Inc. Secures $4 Million in Funding for Clinical Trials and Agrees To Restructure Management
July 20, 2022
Via
ACCESSWIRE
Organicell Regenerative Medicine, Inc. Secures $4 Million in Funding for Clinical Trials and Agrees To Restructure Management
July 20, 2022
MIAMI, FL / ACCESSWIRE / July 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological...
From
Organicell Regenerative Medicine, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Organicell And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients
February 08, 2022
MIAMI, FL / ACCESSWIRE / February 8, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies,...
From
Organicell Regenerative Medicine
Via
AccessWire
Exposures
COVID-19
Organicell Regenerative Medicine, Inc. Provides Updates of Clinical Trial Activities
December 29, 2021
MIAMI, FL / ACCESSWIRE / December 29, 2021 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is...
From
Organicell Regenerative Medicine, Inc.
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.